OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Oncology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis	42
Editorial introductions	33
Treatments and challenges in advanced prostate cancer	30
Optimal management of oligometastatic prostate cancer: current state and future directions	29
Circulating tumor DNA in human papilloma virus negative head and neck squamous cell carcinoma	29
State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies	22
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy	21
Collecting information from all sarcoma reference cancer centres worldwide: achievement and next steps	20
The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies	17
Neurorehabilitation in brain tumours: evidences and suggestions for spreading of knowledge and research implementation	16
Role of PSMA PET/CT in imaging and management of prostate cancer	16
Cancer survivors living with chronic pain: patient and healthcare professional perspectives and current recommendations	14
Editorial introductions	14
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?	14
Epigenetic dynamics of aging and cancer development: current concepts from studies mapping aging and cancer epigenomes	14
Editorial introductions	13
How to prevent human papillomavirus-related oropharyngeal cancer?	13
Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?	13
Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers	13
Neoadjuvant and adjuvant approaches in gastroesophageal cancers	13
Safety of assisted reproductive techniques in gynecological cancer patients	13
Biomarkers and immunotherapy: where are we?	13
Impact of sentinel node use in lymphedema formation among gynecologic cancer patients	13
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification	12
Enhancing proactive life-sustaining treatment preference documentation in advanced cancer care: barriers and recommendations	12

Indications and technique of minimally invasive surgery in early-stage cervical cancer	12
New hopes in relapsed refractory primary central nervous system lymphoma	12
Circulating tumor DNA in breast cancer: a biomarker for patient selection	12
Beyond ‘the good, the bad and the ugly’: let us put rectal cancer patients at the centre of the decision making	12
State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies	12
Open questions on vorasidenib	12
Pregnancy-related hormonal changes and thyroid growth: do they have an impact on the higher incidence of differentiated thyroid cancer in women?	11
The evolving landscape of bispecific antibodies in the treatment of lung cancer	10
Recent highlights and breakthroughs in immunotherapy for head and neck cancers	10
Editorial introductions	10
A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?	10
Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma	10
Recent advances in precision medicine for acute myeloid leukemia	10
Current evidence of integrative oncology modalities for managing adverse effects and survivorship issues among adolescents and young adult (AYA) cancer patients and survivors	9
Pathology and new insights in central nervous system lymphomas	9
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies	9
Interventions aiming to improve advance care planning uptake in oncology: a scoping review of recent randomized controlled trials	9
Liquid biopsy in brain tumors: moving on, slowly	9
Noninvasive skin imaging of melanocytic and nonmelanocytic tumours: recent findings	8
The 5T's of health disparities in multiple myeloma in Latin America	8
Lung cancer screening in never smokers	8
Artificial intelligence in lung cancer: from diagnosis to therapy	8
Machine learning applications and challenges in graft-versus-host disease: a scoping review	8
Editorial introductions	8
Hybrid magnetic resonance and PET imaging for prostate cancer recurrence	8
A new comprehensive and stratified concept for supportive care in cancer patients	8
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results	8
Antibody–drug conjugates in rare genitourinary tumors: review and perspectives	8
Melanoma in adolescents and young adults: special considerations	7
How to become a Multinational Association of Supportive Care in Cancer-designated center of excellence in supportive care in cancer	7
Application of single-port techniques in endometrial cancer	7
State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies	7
Breast surgery after neoadjuvant therapy	7
Controversies on chemotherapy for early HR+/HER2− breast cancer: the role of anthracyclines and dose intensification	7
Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification)	7
Current role and indications of minimally invasive surgery in gynecologic oncology	7
Editorial introductions	7
Potential application of artificial intelligence in cancer therapy	7
Editorial introductions	7
Evolving paradigms in the management of basal cell carcinoma	7
Editorial introductions	7
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients	7
New therapies for brain metastases: an update	7
Advantages of robotic surgery in obese patients with endometrial cancer	7
Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results	7
Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments	6
Achievements of international rare cancers networks and consortia in the neuro-oncology field	6
Editorial introductions	6
How to monitor the side effects of treatments in cancer patients	6
Adjuvant and neoadjuvant approaches in pancreatic cancer	6

Preclinical glioma models in neuro-oncology: enhancing translational research	6
Pathologic diagnosis of lung cancer – recent developments	6
Treatment of radiation-associated angiosarcoma	6
How to treat localized Hodgkin lymphoma?	6
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer	6
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma	6
Global priorities for advancing cancer survivorship	6
Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer	6
Sarcoma incidence worldwide: regional differences in histology and molecular subtypes	6
Precision, personalization, and quality of life for patients with lymphoma	6
Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine	6
When do I ask for a DNA methylation array for primary brain tumor diagnosis?	6
Cellular therapies in sarcoma and other solid tumors	6
Targeting cancer stem cell pathways for lung cancer therapy	6
HER2-positive breast cancer: cotargeting to overcome treatment resistance	6
Immunotherapies in non-metastatic gastrointestinal cancers	6